CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This is a randomized, double-blind, sham-controlled, adaptive-design pivotal study of sensory stimulation in subjects with mild to moderate Alzheimer's...
Matthews, North Carolina, United States and 67 other locations
This study is designed to evaluate safety and efficacy of fosgonimeton (ATH-1017) in the treatment of mild to moderate Alzheimer's disease...
Phase 2, Phase 3
Charlotte, North Carolina, United States and 89 other locations
reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early symptomatic Alzheimer's...
Phase 3
Matthews, North Carolina, United States and 75 other locations
is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Tri...
Phase 3
Matthews, North Carolina, United States and 117 other locations
This is an open-label long term extension study for participants with Alzheimer's disease (AD) who have completed Protocol TB006AD2...
Phase 2
Matthews, North Carolina, United States and 12 other locations
administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's...
Phase 2
Matthews, North Carolina, United States and 96 other locations
be from 2 clinical subgroups: mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild Alzheimer's disease...
Phase 2
Charlotte, North Carolina, United States and 168 other locations
This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determin...
Phase 3
Charlotte, North Carolina, United States and 246 other locations
The aim of this study is to assess the efficacy and safety of GSK4527226 in participants with early Alzheimer's Disease (AD) (inclu...
Phase 2
Matthews, North Carolina, United States and 103 other locations
Randomized efficacy and safety study of piromelatine 20 mg versus placebo in participants with mild dementia due to Alzheimer's disease...
Phase 2, Phase 3
Matthews, North Carolina, United States and 36 other locations
Clinical trials
Research sites
Resources
Legal